Advanced search×

Positron emission tomography for benign and malignant disease.

Anthony A Visioni and Julian J Kim

Surg Clin North Am 91(1):249-66 (2011) PMID 21184913

Functional imaging using radiolabeled probes that specifically bind and accumulate in target tissues has improved the sensitivity and specificity of conventional imaging. Fluorodeoxyglucose (FDG)-positron emission tomography (PET) has shown improved diagnostic accuracy in differentiating benign from malignant lesions in the setting of solitary pulmonary nodules. FDG-PET has become useful in preoperative staging of patients with lung cancer, and is being tested with many other malignancies for its ability to change patient management. This article provides an overview of the current status of FDG-PET and presents the challenges of moving toward routine use.

DOI: 10.1016/j.suc.2010.10.012
Version: za2963e q8za1 q8zbc q8zc8 q8zdc q8ze1 q8zfc q8zg7
View PDF

Similar articles you may find interesting…

  1. PET/CT-guided radiation therapy planning: from present to the future.
    T T Gupta and S S Beriwal

    Audio, Transactions of the IRE Profession... 47(2):126-33 (2010) PMID 20448373

    Molecular imaging using 18F-fluoro-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) has been successfully used in the diagnosis, initial staging, and response assessment of various malignant tumors. Advances in radiation therapy planning and delivery have ushered in the era...
  2. Clinical applications of positron emission tomography-computed tomography in oncology.
    R R Kumar, D D Halanaik, and A A Malhotra

    Audio, Transactions of the IRE Profession... 47(2):100-19 (2010) PMID 20448371

    Positron emission computed tomography (PET) is a functional diagnostic imaging technique, which can accurately measure in vivo distribution of a variety of radiopharmaceuticals. The ability of PET to study various biological processes (glucose, amino acid, phospholipids, receptors etc.) opens up new...
  3. Role of positron emission tomography (PET) in head and neck cancer
    M M Duet, F F Hugonnet, and M M Faraggi

    Eur Ann Otorhinolaryngol Head Neck Dis 127(1):6 (2010) PMID 20822756

    F-18 fluorodeoxyglucose positron emission tomography is now part of the initial stage III and IV cancer work-up and each time that metastasis or the presence of a second cancer is suspected that may contraindicate major surgery. Similarly, this exam should be undertaken when the conventional work-up...